Max Planck Institute for Experimental Medicine

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Retrieved on: 
Friday, January 13, 2023
Stanford University School of Medicine, Nobel Prize, Cell, Nobel Prize in Physiology or Medicine, SAB, Brain, Sanofi, University, Max Planck Institute for Experimental Medicine, Howard Hughes Medical Institute, Yale School of Medicine, Division, Biophysics, Regulation of tobacco by the U.S. Food and Drug Administration, School, Avram Goldstein, Stanford University, Research, Center for Drug Evaluation and Research, Food, Synapse, Neuron, Neurotransmission, University of California, San Francisco, United States Air Force Scientific Advisory Board, Pharmaceutical industry, Medical device, University of Texas Southwestern Medical Center, Physiology, Medicine, Neuroscience

Dr. Südhof's appointment further strengthens the company's scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.

Key Points: 
  • Dr. Südhof's appointment further strengthens the company's scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.
  • On joining the SAB, Dr. Südhof will support the Company's leadership in its oversight and scrutiny of the Company's research and clinical development strategies.
  • Commenting on the appointment, Dr. Guosong Liu, Chairman and CEO of Neurocentria, said: "I am delighted to welcome Tom to Neurocentria.
  • In 2008, Dr. Südhof moved to Stanford University and became the Avram Goldstein Professor in the School of Medicine.

Medikine Appoints Roland Buelow, Ph.D., to Board of Directors

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Biotechnology, Maintenance, Therapy, Celgene, Seagen, Rabbit, Amgen, Genetics, Cytokine, Infection, Pfizer, SITC, Drug discovery, THP, IL-7, Johnson & Johnson, AbbVie, Janssen Pharmaceuticals, Cancer, Degenerative disease, Society, Research, AstraZeneca, Stanford University, Society for Immunotherapy of Cancer, Merck Group, Max Planck Institute for Experimental Medicine, Antibody, Growth, University, Engineering, Half-life, Immunotherapy, Moses Austin, Janssen, OMT, Pharmaceutical industry, Fine chemical, Vaccine

Medikine, Inc., a clinical-stage biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE technology, today announced the appointment of Roland Buelow, Ph.D., to the companys board of directors.

Key Points: 
  • Medikine, Inc., a clinical-stage biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE technology, today announced the appointment of Roland Buelow, Ph.D., to the companys board of directors.
  • The board and management look forward to working closely with him as Medikine enters its next phase of growth as a clinical-stage company.
  • He later founded Ancora Biotech, where he currently serves as the chairman of the board.
  • Medikine also shared detailed preclinical results for MDK-1654, Medikines dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINES.

Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases

Retrieved on: 
Monday, November 28, 2022
Research, Pharmaceutical, Robotics, Mental Health, Medical Devices, Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, FDA, Health, PrimeSense, Compound, Magnetism, Khosla Ventures, Use, Engineering, Prevalence, Max Planck Institute for Experimental Medicine, IND, Safety, Brain, Facial recognition, Toxicity, Neuroscience, Ageing, Neurodegeneration, 3D, Pectus carinatum, Central nervous system, Deep Insight, Drug development, OurCrowd, CNS, Face ID, IDE, Hydrocephalus, Revolution, Max Planck Society, Robotics, BNL, Therapeutic index, Huntington's disease, Therapy, Venture, Traffic barrier, Biology, Glioma, FDA, Medical device, Pharmaceutical industry, Medical imaging, Labs, Apple

By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.

Key Points: 
  • By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.
  • Funds will be used to advance clinical development of the companys lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder).
  • Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough.
  • We are extremely excited about the transformative potential Bionaut presents in treating debilitating neurological disorders, said Vinod Khosla, founder of Khosla Ventures.

Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Lists of diseases, Janelia Research Campus, National Academy of Medicine, Harvard Medical School, Ion, Patient, Aldo, Max Planck Society, Research, Max Planck Institute for Experimental Medicine, Bardet–Biedl syndrome, Doctor of Philosophy, Emory University School of Medicine, Hospital, PKD, Coronavirus Scientific Advisory Board (Turkey), Investment, Therapy, Neuroscience, Neurodegeneration, Nobel Prize, Company, BBS, Biophysical chemistry, Polycystic kidney disease, Nephronophthisis, Internal medicine, SAB, Howard Hughes Medical Institute, HHMI, National academy, National, Pharmaceutical industry, Brigham, Caraway, MD

Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the companys Scientific Advisory Board (SAB).

Key Points: 
  • Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the companys Scientific Advisory Board (SAB).
  • I am delighted to welcome Dr. Clapham to Caraway as a scientific advisor, said Martin D. Williams, Chief Executive Officer at Caraway Therapeutics.
  • The combined cutting-edge expertise and wisdom David provides will be a key asset for Caraway as we continue to advance our programs.
  • Dr. Clapham joins Caraways experienced, collaborative, and dedicated Scientific Advisory Board team comprised of tenured biologists and biotech leaders.

Palantir and Dewpoint Therapeutics Announce Strategic Partnership

Retrieved on: 
Monday, December 20, 2021
Technology, Infectious Diseases, Genetics, Clinical Trials, Software, Other Health, Biotechnology, Health, Data Management, Oncology, Forward-looking statement, Therapy, U.S. Securities and Exchange Commission, LinkedIn, Foundry, Infection, Biology, Decision-making, Securities Exchange Act of 1934, Maritime Transportation Security Act of 2002, Cell, Max Planck Society, NYSE, Daou Technology Inc., Cancer, Time, Whitehead, Securities Act of 1933, Lists of diseases, Drug design, Dew point, Drug discovery, Machine learning, Inflammation, Security (finance), PLTR, Laboratory, Neurodegeneration, Software, Twitter, Partnership, Max Planck Institute for Experimental Medicine, Pharmaceutical industry, Risk management, Medical imaging, Biotechnology, Biomolecular Condensates, Dewpoint Therapeutics, Palantir Technologies Inc., BIOMOLECULAR CONDENSATES, DEWPOINT THERAPEUTICS, PALANTIR TECHNOLOGIES INC.

Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (Dewpoint"), the leading biomolecular condensates company, today announced a partnership for Palantirs Foundry platform to help power Dewpoints efforts to discover treatments and cures for the most challenging diseases.

Key Points: 
  • Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (Dewpoint"), the leading biomolecular condensates company, today announced a partnership for Palantirs Foundry platform to help power Dewpoints efforts to discover treatments and cures for the most challenging diseases.
  • Palantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision making.
  • At Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.
  • Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

Retrieved on: 
Wednesday, December 15, 2021
Method, Therapy, Hope, Company, Brain, Therapeutic index, Doctor of Philosophy, Toxicity, Max Planck Society, CNS, Organic acid, Nasdaq, Private Securities Litigation Reform Act, Cancer, SEC, CEO, Research, Safety, Patient, Disease, HSV, Neoplasm, Engineering, Immunogenic cell death, MD, Virus, Potyvirus, GLOBE, CADL, Content discovery platform, Mouse, Technology, Max Planck Institute for Experimental Medicine, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Candel, Fellow of the Academy of Medical Sciences

Bionaut Labs is excited to partner with Candel, a leader in developing oncolytic viruses for multiple cancers, to advance much-needed treatment options for brain cancer patients leveraging our transformative Bionaut platform technology," said Michael Shpigelmacher, co-founder and CEO, Bionaut Labs.

Key Points: 
  • Bionaut Labs is excited to partner with Candel, a leader in developing oncolytic viruses for multiple cancers, to advance much-needed treatment options for brain cancer patients leveraging our transformative Bionaut platform technology," said Michael Shpigelmacher, co-founder and CEO, Bionaut Labs.
  • Through precise targeting, Bionaut therapeutics could offer better efficacy and safety that cannot be achieved by other traditional treatment or delivery modalities.
  • Candel is a late clinical-stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Genetron Health’s Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021

Retrieved on: 
Monday, August 30, 2021
Translation, Company, Columbia University, Glioma, IDH1, Neuroscience, Prognosis, Cancer, Physician, Diagnosis, Molecular biology, GLOBE, GTH, SEC, International Prize (Fyssen Foundation), Duke University School of Medicine, Research, Classification, Private Securities Litigation Reform Act, Neuro-Oncology (journal), Max Planck Institute for Experimental Medicine, Doctor of Philosophy, World, Forward-looking statement, Entrepreneurship, Lists of diseases, Achievement, Max Planck Society, IDH2, Translational neuroscience, NASDAQ, Surgeon, WHO, List of colleges of physicians, Patient, Genetics, Columbia University Vagelos College of Physicians and Surgeons, Recurrence, Phrase, Johns Hopkins University, Mike Hopkins (basketball), Central nervous system, Neoplasm, Central nervous system tumor, Pharmaceutical industry

BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021.

Key Points: 
  • BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021.
  • Dr. Yan co-founded Genetron Health and became the companys Chief Scientific Officer.
  • The International Prize for Translational Neuroscience of the Gertrud Reemtsma Foundation is one of the most prominent international prizes for translational neuroscience.
  • Nominees should be individuals whose seminal discoveries and major scientific contributions constitute an original and significant achievement in translational neuroscience.